CD8A and neoplasm: Previous studies have linked the proliferation of peripheral effector T cells to favorable outcomes in immunotherapy, and an increase in tumor-specific CD8+ and CD4+ effector T cells within peripheral tissues is advantageous for inhibiting tumor progression (24).